Guggenheim analyst Michael Schmidt maintained a Buy rating on Compass Therapeutics (CMPX – Research Report) today and set a price target of ...

Teacher Retirement System of Texas increased its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 26.4% ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report) saw unusually large options trading activity on Friday. Traders acquired 12,381 call options on the stock. This represents an increase of ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sana Biotechnology (SANA – Research Report), Insmed (INSM – Research Report) a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

SpringWorks Therapeutics portfolio features Ogsiveo for desmoid tumors and Gomekli for NF1‑plexiform neurofibromas. In fact, Ogsiveo’s revenues alone reached $172 million in 2024, supported by ...

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even as its shares tumbled more than 14%, marking their worst weekly decline ...

The FDA has approved SpringWorks Therapeutics’s mirdametinib (Gomekli) for adult and paediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic ...